Dr Robin Young Consultant Medical Oncologist Sheffield Cancer Research Centre.
-
Upload
pauline-parsons -
Category
Documents
-
view
236 -
download
5
Transcript of Dr Robin Young Consultant Medical Oncologist Sheffield Cancer Research Centre.
Studying angiosarcoma in dogs
Dr Robin YoungConsultant Medical Oncologist
Sheffield Cancer Research Centre
SarcomaUK funded project 2012/13◦ ‘Studies in angiosarcoma using canine tumours’
1. What made you decide to research into Sarcoma? 2. How did you arrive at your research question? 3. What has your research shown? 4. How will this benefit patients?
Overview
Subtype of soft tissue sarcoma
Rare, aggressive vascular tumour (tumour of blood vessels)
Can develop anywhere. Most commonly:◦ Scalp in older white males◦ Secondary tumours in women previously treated for breast
cancer with radiotherapy
Treatments for angiosarcoma include surgery, radiotherapy and chemotherapy, but often treatment is very challenging
Angiosarcoma
Advances in the treatment of angiosarcoma have been limited by its rarity.
Few models of human angiosarcoma for laboratory research
Comparative oncology◦ Study of cancer in other species◦ Bone cancer in dogs (Osteosarcoma)
Mifamurtide◦ Canine angiosarcoma
Angiosarcoma
Studies in angiosarcoma using
canine tumours
2006 – commenced specialist training in medical oncology at Weston Park Hospital, Sheffield
2009-2012 – YCR clinical research fellow ‘Vascular targeted agents for the treatment of angiosarcoma’
2013 – Clinical lecturer in medical oncology
2015 – Consultant medical oncologist specialising in sarcoma, Sheffield
1. What made you decide to research into Sarcoma?
3 year YCR clinical research fellowship◦ Tumour Microcirculation Research Group,
University of Sheffield◦ Supervisors:
Prof Penella Woll – sarcoma Prof Nicola Brown – vascular biology
2. How did you arrive at your research question?
2. How did you arrive at your research question?
In 1971, Judah Folkman reported that cancers are dependent upon a blood supply for tumour growth and spread.
Drugs that target the tumour blood supply represent potential therapy for cancer (vascular targeting agents).◦ Bevacizumab (Avastin)
• Angiosarcomas are vascular tumours
• ?angiosarcoma response to vascular targeting agents
• Axitinib – oral tablet vascular targeting agent
• Axi-STS – a UK, early clinical trial, led by Prof Woll, of Axitinib for advanced soft tissue sarcoma, including angiosarcoma
2. How did you arrive at your research question?
• YCR clinical research fellowship Laboratory studies Analysing a panel of human vascular tumour samples
(haemangiomas, angiosarcomas) Studying the response of 2 human angiosarcoma cell
lines to vascular targeted agents in different assays (proliferation, differentiation, migration, invasion)
2. How did you arrive at your research question?
2. How did you arrive at your research question?
Potentially interesting results, particularly with a class of agents called vascular disrupting agents
Vadimezan
2. How did you arrive at your research question? 2 human
angiosarcoma cell lines
No in vivo model of human angiosarcoma
How to take this research forward?
Connective Tissue Oncology Society Annual Meeting 2010
Dr Nick Duesbery Van Andel Research
Institute, Grand Rapids, USA
2. How did you arrive at your research question?
British Sarcoma Group Annual Meeting 2011
Dr Sue Murphy Animal Health Trust,
Cambridge, UK
2. How did you arrive at your research question?
Human angiosarcoma Canine angiosarcoma
Morphology similar Morphology similar
Aggressive tumours Aggressive tumours
Rare Common (German Shepherds)
PrimarySecondary
Primary
Cutaneous Visceral
‘Studies in angiosarcoma using canine tumours’ Aims:
◦ To analyse a large panel of canine angiosarcoma tumour samples using PCR, to quantify their expression of vascular growth factors.
◦ To assess the response of canine angiosarcoma cell lines to vascular targeted therapy.
◦ To compare the results with our studies of human angiosarcoma.
3. What has your research shown?
Canine angiosarcoma is a useful model for studying human angiosarcoma.
3. What has your research shown?
4. How will this benefit patients? Clinical trial with the Animal Health Trust of
a Vascular Disrupting Agent for canine angiosarcoma patients?
A potential way of informing a clinical trial in human patients?
4. How will this benefit patients?
Currently undertaking laboratory studies using human angiosarcoma cell lines to validate the findings from the studies at VARI of canine angiosarcoma cell lines.
Collect data to support a proposal for an early phase clinical trial of combination therapy for the treatment of angiosarcoma in human patients.
4. How will this benefit patients?
Thankyou! Professor Penella Woll Professor Nicola Brown Dr Malee Fernando Dr Sue Murphy Dr Nick Duesbery